Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors

The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show, in multiple complementary models, that...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S., Pratilas, Christine A., Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V., Tadi, Madhavi, Rogers, Andrew, Repellin, Claire, Capelletti, Marzia, Maertens, Ophélia, Goetz, Eva M., Letai, Anthony, Garraway, Levi A., Lazzara, Matthew J., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477553/
https://ncbi.nlm.nih.gov/pubmed/22961667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items